SCHEMBL3548826

SCHEMBL3548826

COC(=O)c1cc(OC)c(OC)c(C(=O)N(C)C)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 2/20 0.50
PDE3A Q14432 2/20 0.50
PDE1A P54750 1/20 0.50
PDE1B Q01064 1/20 0.50
PDE1C Q14123 1/20 0.50
KDM4E B2RXH2 4/20 0.46
POLB P06746 2/20 0.46
SCN1A P35498 1/20 0.46
SCN2A Q99250 1/20 0.46
SCN3A Q9NY46 1/20 0.46
CYP3A4 P08684 1/20 0.46
TPMT P51580 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
PDE5A O76074 1/20 0.44
PDE4A P27815 1/20 0.44
PDE4B Q07343 1/20 0.44
PDE4C Q08493 1/20 0.44
PDE4D Q08499 1/20 0.44
USP2 O75604 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl Syringate SCHEMBL211747 0.81 MEN1 (0.61) KDM4EPOLBCYP3A4TPMTMEN1
SCHEMBL10322842 0.80 NOTUM (0.44) PDE3BPDE3APDE1APDE1BPDE1C
SCHEMBL3549967 0.79 MAPT (0.55) KDM4ECYP3A4MEN1KMT2AUSP2
SCHEMBL7384063 0.78 KDM4E (0.49) PDE3BPDE3APDE1APDE1BPDE1C
SCHEMBL7376402 0.78 TUBB4A (0.51) KDM4ESCN1ASCN2ASCN3ACYP3A4
SCHEMBL17655659 0.76 TPMT (0.53) KDM4EPOLBCYP3A4TPMTMEN1
SCHEMBL1134668 0.76 TPMT (0.73) KDM4EPOLBCYP3A4TPMTMEN1
SCHEMBL5240311 0.76 MEN1 (0.49) KDM4EPOLBSCN1ASCN2ASCN3A
SCHEMBL24425750 0.75 KMT2A (0.54) KDM4EPOLBCYP3A4TPMTMEN1
SCHEMBL3549740 0.75 KDM4E (0.48) KDM4EPOLBSCN1ASCN2ASCN3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE PDE3B 2713/4885PDE3A 1590/4885PDE1A 2976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.